Clinical Trial Update: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment [Phase 1, Phase 2]

View source ↗

Summary

The update reports on the relative bioavailability/bioequivalence of different selinexor formulations, the impact of hepatic impairment on selinexor pharmacokin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Other Solid Tumors

Drugs mentioned

• Selinexor (Xpovio) (Selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) | Phase 1, Phase 2 | Status: COMPLETED